Alzheimer's - ADDF/Belfer ApoE Therapeutics Innovation Programme ($ 1,000,000)

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert and Renée Belfer Family Foundation invite applications for the ADDF/Belfer ApoE Therapeutics Innovation Programme. The upcoming deadline for submission of a full proposal is September 5, 2013. The Letter of Intent is due two weeks before the proposal deadline. The programme has been established to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. Funding is up to $ 1,000,000 per application.

ADDF funds drug discovery research programmes from investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.